Jazz Pharmaceuticals (NAS: JAZZ) is expected to report Q2 earnings around Aug. 7. Here's what Wall Street wants to see.
The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict Jazz Pharmaceuticals' revenues will expand 94.5% and EPS will improve 49.3%.
The average estimate for revenue is $125.6 million. On the bottom line, the average EPS estimate is $1.06.
Last quarter, Jazz Pharmaceuticals notched revenue of $108.4 million. GAAP reported sales were much higher than the prior-year quarter's $50.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.91. GAAP EPS of $0.48 were the same as the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 92.3%, 220 basis points worse than the prior-year quarter. Operating margin was 38.4%, 600 basis points worse than the prior-year quarter. Net margin was 25.5%, 1,740 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $599.6 million. The average EPS estimate is $4.66.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 212 members out of 282 rating the stock outperform, and 70 members rating it underperform. Among 74 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 47 give Jazz Pharmaceuticals a green thumbs-up, and 27 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Jazz Pharmaceuticals is outperform, with an average price target of $61.67.
Over the decades, small-cap stocks like Jazz Pharmaceuticals have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Get instant access to this free report.
Add Jazz Pharmaceuticals to My Watchlist.
The article Will Jazz Pharmaceuticals Beat These Analyst Estimates? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is the co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.